As is well known, immunosuppressive treatment (IS) after liver transplantation has several
and frequents adverse effects that limit the survival of the graft and recipients. Because of
that, it is desirable that these recipients were able to receive a mild IS regime with a
better safety profile. An attempt to get that aim has been evaluated in several trials in the
past, and consist in to change the IS regime from an calcineurin inhibitors (CNI) based to
another less intense and with less adverse effects based on mycophenolate mofetil (MMF),
which is known to have a better safety profile. The success rate of this strategy(i.e.
complete conversion in absence of rejection) has a wide range from 100% to 50% approximately.
However it is accepted that this strategy is associated with the improvement of several
adverse effects of CNIs such as renal failure and dyslipemia. This study's aim is to perform
IS conversion from CNI to MMF monotherapy and look for transcriptional biomarkers employing a
whole genome expression study performed with microarrays at baseline on liver tissue and/or
PBMCs to try to find a differential gene expression able to correlate with a successful
conversion and thus, to generate a set of transcriptional biomarkers potentially able to
predict the result of the IS conversion on an independent cohort of liver recipients.